Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab.

Philippe SultanikClaudia CampaniEdouard LarreyBertille CampionManon EvainCharles RouxLorraine BlaiseMathilde WagnerMarika RudlerJean Charles NaultDominique ThabutManon Allaire

Published in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2024)

PHT-related events significantly affect not only liver decompensation but also OS in AtezoBev-treated patients. We suggest a more widespread use of NSBB to prevent liver decompensation, with intensified prophylaxis for high-risk patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
blood pressure
prognostic factors
peritoneal dialysis
patient reported outcomes
patient reported